Anthem Inc. Announces Changes to Leadership Team

Rhea-AI Summary

Anthem, Inc. (NYSE: ANTM) has announced significant senior leadership changes aimed at positioning the company for future growth. Effective October 5, Pete Haytaian will lead the diversified business group and IngenioRx, while Morgan Kendrick will take charge of Anthem’s commercial business. Rajeev Ronanki has been appointed as President of Digital Platforms, focusing on enhancing the company's digital capabilities. These changes reflect Anthem's commitment to deliver innovative health solutions and adapt to evolving consumer needs.

Positive

• Leadership changes expected to drive growth and innovation.
• Pete Haytaian's experience in commercial and government business enhances strategic direction.
• Morgan Kendrick brings extensive knowledge of Anthem's commercial markets.
• Rajeev Ronanki's digital expertise aims to strengthen Anthem's digital health platform.

Negative

• None.

INDIANAPOLIS--(BUSINESS WIRE)-- Anthem, Inc. (NYSE: ANTM) announced today organizational changes to the senior leadership team reflecting the company’s continued positioning for future growth and preparing to meet the evolving needs of the industry, its consumers and the communities they serve.

“The breadth and depth of our leadership ensures that we stand ready to deliver on our promises to those we are privileged to serve and our commitment to drive health beyond healthcare,” said Gail Boudreaux, President and CEO. “Collectively, these individuals are industry leaders who are dedicated to driving growth, change and innovation as we work to become a lifetime, trusted health partner.”

The following changes are effective Tuesday, October 5:

• Pete Haytaian will lead Anthem’s diversified business group and IngenioRx as Executive Vice President and President, Diversified Business and IngenioRx. Most recently, Haytaian served as President of Commercial and Specialty Business, where for the past three years he has delivered industry-leading growth, while responding to economic and market pressures, as well as uncertainty amid the pandemic. Having also led Anthem’s Government Business Division through transformative growth, Haytaian brings to this role a deep knowledge of the healthcare industry and Anthem’s government and commercial businesses and the potential of the company’s diversified business and pharmacy benefits business.

• Morgan Kendrick will lead Anthem’s commercial business, as Executive Vice President and President, Commercial and Specialty Business Division, joining Anthem’s Senior Leadership Team. Kendrick joined Anthem in 1995 and has driven innovation and market-leading growth across key lines of commercial business including in his roles as President of Anthem National Accounts and President of Commercial Business in Georgia. Kendrick has served as President of the Commercial West Markets since 2020, leading the performance, growth, and strategic direction for Anthem’s commercial business in California, Colorado, Indiana, Kentucky, Missouri, Nevada, Ohio, and Wisconsin, as well as Specialty sales across the company’s 14 local commercial markets.

• Rajeev Ronanki has been named President, Digital Platforms, joining Anthem’s Senior Leadership Team. As the company accelerates its strategy to become a digital platform for health, Ronanki will be responsible for growing and commercializing Anthem’s digital capabilities for consumers, care providers, and the health ecosystem as the company works to reinvent care delivery, operations, and interactions. Since joining Anthem in 2018, Ronanki has led Anthem’s digital transformation by developing our digital-first approach across our Digital, Artificial Intelligence (AI), Exponential Technology, Service Experience, and Innovation portfolios.

About Anthem, Inc.

Anthem is a leading health benefits company dedicated to improving lives and communities, and making healthcare simpler. Through its affiliated companies, Anthem serves more than 117 million people, including more than 44 million within its family of health plans. We aim to be the most innovative, valuable and inclusive partner. For more information, please visit www.antheminc.com or follow @AnthemInc on Twitter.

Forward-Looking Statements

This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,” “project,” “forecast,” “plan” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these forward- looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent otherwise required by federal securities laws, we do not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof. These risks and uncertainties include, but are not limited to: the impact of large scale medical emergencies, such as public health epidemics and pandemics, including COVID-19, and catastrophes; trends in healthcare costs and utilization rates; our ability to secure sufficient premium rates, including regulatory approval for and implementation of such rates; the impact of federal and state regulation, including ongoing changes in the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, as amended; changes in economic and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; our ability to contract with providers on cost-effective and competitive terms; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic growth opportunities; reduced enrollment; unauthorized disclosure of member or employee sensitive or confidential information, including the impact and outcome of any investigations, inquiries, claims and litigation related thereto; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star ratings and other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations, audits or reviews; risks and uncertainties related to our pharmacy benefit management (“PBM”), business including non-compliance by any party with the PBM services agreement between us and CaremarkPCS Health, L.L.C.; medical malpractice or professional liability claims or other risks related to healthcare and PBM services provided by our subsidiaries; general risks associated with mergers, acquisitions, joint ventures and strategic alliances; changes in U.S. tax laws; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness; a downgrade in our financial strength ratings; the effects of any negative publicity related to the health benefits industry in general or us in particular; failure to effectively maintain and modernize our information systems; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; the impact of international laws and regulations; intense competition to attract and retain employees; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211005006188/en/

Investor Relations:

Stephen Tanal

Stephen.tanal@anthem.com

Media Relations:

Michelle Vanstory

Michelle.vanstory@anthem.com

Source: Anthem, Inc.

FAQ

What are the recent leadership changes at Anthem, Inc.?

Anthem announced that Pete Haytaian, Morgan Kendrick, and Rajeev Ronanki have been appointed to key leadership roles effective October 5.

Who is leading Anthem's diversified business and IngenioRx?

Pete Haytaian has been named Executive Vice President and President of the Diversified Business and IngenioRx.

What role will Morgan Kendrick play in Anthem?

Morgan Kendrick will lead Anthem’s commercial business as Executive Vice President and President of the Commercial and Specialty Business Division.

What is Rajeev Ronanki's new position at Anthem?

Rajeev Ronanki has been appointed President of Digital Platforms, focusing on Anthem's digital capabilities.

How might these leadership changes impact Anthem, Inc. (ANTM)?

The leadership changes are expected to enhance Anthem's ability to innovate and respond to evolving consumer needs, potentially driving growth.